Publications by authors named "Jason B Cross"

Claim this Profile
C
Characterization of the KRas G12D-inhibitor interactions by differential HDX-MS and molecular dynamics simulations.
Evgeniy V Petrotchenko, Brandon Novy, Edith Nagy, Konstantin I Popov, Jason B Cross

Comput Struct Biotechnol J· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors.
Foroughsadat Absar, Brandon Novy, Edith Nagy, Evgeniy V Petrotchenko, Konstantin I Popov, Jason B Cross

Anal Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric targeting of RIPK1: discovery of novel inhibitors parallel virtual screening and structure-guided optimization.
R S K Vijayan, Matthew M Hamilton, Dana E Pfaffinger, Fernando G Alvarez, Naphtali J Reyna, Jason B Cross

RSC Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.
Xiuning Le, Jacqulyne P Robichaux, Monique Nilsson, R S K Vijayan, Ashwin Ravichandran, Jason B Cross

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers.
Christopher L Carroll, Michael G Johnson, Yanbing Ding, Zhijun Kang, R S K Vijayan, Jason B Cross

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy.
Kang Le, Michael J Soth, Jason B Cross, Gang Liu, William J Ray

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, Mehmet Altan, Hai Tran, Jason B Cross

Cancer Cell· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening of Hydrocarbon-Stapled Peptides for Inhibition of Calcium-Triggered Exocytosis.
Ying Lai, Michael J Tuvim, Jeremy Leitz, John Peters, Richard A Pfuetzner, Jason B Cross

Front Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing preclinical drug discovery with artificial intelligence.
R S K Vijayan, Jan Kihlberg, Jason B Cross, Vasanthanathan Poongavanam

Drug Discov Today· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 6-[(3,4)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor.
Barbara Czako, Yuting Sun, Timothy McAfoos, Jason B Cross, Paul G Leonard

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Jacqulyne P Robichaux, Xiuning Le, R S K Vijayan, J Kevin Hicks, Simon Heeke, Jason B Cross

Nature· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Matthew M Hamilton, Faika Mseeh, Timothy J McAfoos, Paul G Leonard, Naphtali J Reyna, Jason B Cross

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cork-in-bottle mechanism of inhibitor binding to mammalian complex I.
Injae Chung, Riccardo Serreli, Jason B Cross, M Emilia Di Francesco, Joseph R Marszalek

Sci Adv· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Yuting Sun, Brooke A Meyers, Barbara Czako, Paul Leonard, Faika Mseeh, Jason B Cross

Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Barbara Czako, Joseph R Marszalek, Jason P Burke, Pijus Mandal, Paul G Leonard, Jason B Cross

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Jason B Cross

Cancer Cell· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Jason B Cross

Cancer Cell· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods for Virtual Screening of GPCR Targets: Approaches and Challenges.
Jason B Cross

Methods Mol Biol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
Jennifer R Molina, Yuting Sun, Marina Protopopova, Sonal Gera, Madhavi Bandi, Jason B Cross

Nat Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-silico guided discovery of novel CCR9 antagonists.
Xin Zhang, Jason B Cross, Jan Romero, Alexander Heifetz, Eric Humphries

J Comput Aided Mol Des· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based discovery of LpxC inhibitors.
Jing Zhang, Audrey Chan, Blaise Lippa, Jason B Cross, Christopher Liu

Bioorg Med Chem Lett· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design.
Jason B Cross, Jing Zhang, Qingyi Yang, Michael F Mesleh, Jan Antoinette C Romero

ACS Med Chem Lett· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent and selective MTH1 inhibitors.
Alessia Petrocchi, Elisabetta Leo, Naphtali J Reyna, Matthew M Hamilton, Xi Shi, Jason B Cross

Bioorg Med Chem Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB.
Michael F Mesleh, Jason B Cross, Jing Zhang, Jan Kahmann, Ole A Andersen

Bioorg Med Chem Lett· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors.
Jing Zhang, Qingyi Yang, Jason B Cross, Jan Antoinette C Romero, Katherine M Poutsiaka

J Med Chem· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis